Johnson & Johnson's (JNJ) better-than-expected Q2 results and raised full-year outlook are seen as "encouraging" versus the current macro environment, RBC Capital analysts said in a Wednesday note.
The drugmaker is also well-positioned to meet or exceed its full-year guidance as its pharmaceutical and medtech businesses continue to grow, the analysts said.
Growth in core drugs such as Darzalex, Tremfya, and Erleada and share gains in medtech, are expected to sustain revenue through year-end, the firm said.
RBC said that the company's innovation pipeline and broad-based execution support long-term confidence in its outlook.
RBC raised its price target to $185 from $181 and maintained an outperform rating on the stock.
Price: 163.01, Change: -1.77, Percent Change: -1.07
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。